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Abstract
Background: Distortion of taste sensations is a common chemotherapy-induced side effect; however, treatment
evidence is limited. Pilot data indicated that acupuncture might be able to improve symptoms of dysgeusia. Thus,
the aim of this study is to investigate the effects and side effects of hypoglossal acupuncture in the treatment of
dysgeusia in patients with breast cancer undergoing chemotherapy.
Methods/design: The study is a randomized controlled trial comparing a single verum acupuncture treatment with
two active comparators: sham acupuncture and dietary recommendations. Sample size calculation revealed a total
of 75 patients pending an alpha of 0.05, a power of 0.8, and an estimated effect size of 0.80. Patients with breast
cancer undergoing platinum- or taxane-based chemotherapy will be included if they present with phantogeusia
(abnormal taste sensations without an external oral stimulus) with an intensity of 4 points or above on an 11-point
numeric rating scale (NRS). The primary outcome is phantogeusia; secondary outcomes include parageusia (abnormal
taste of food), hypogeusia (reduced taste sensations), hypergeusia (increased taste sensations), xerostomia (dry mouth),
stomatitis, appetite, and functional impairment. All outcomes will be assessed at baseline and prior to the next
chemotherapy administration using an 11-point NRS for each. All adverse events will be recorded.
Discussion: The results of this study will demonstrate the extent to which hypoglossal acupuncture may influence the
intensity of and functional impairment due to chemotherapy-induced dysgeusia.
Trial registration: Clinical Trials.gov, NCT02304913. Registered on 19 November 2014.
Keywords: Acupuncture, Cancer, Chemotherapy, Dysgeusia, Taste disorders, Randomized controlled trial
Background
Taste disorders are frequent side effects in patients
treated with chemotherapy [1, 2]. According to the
National Cancer Institute Common Terminology
Criteria for Adverse Events, dysgeusia is defined as a
disorder characterized by abnormal or impaired sense of
taste with mostly unpleasant metallic, bitter, or salty
alteration of taste sensations [3]. Subconditions of
dysgeusia include phantogeusia, an abnormal sensation
of taste without presence of an external oral stimulus;
parageusia, an abnormal taste of food; hypogeusia, a re-
duced sensation of taste; and hypergeusia, an increased
sensation of taste. Although most forms of dysgeusia
present persistent courses in quite a few cases, preva-
lence during chemotherapy ranged between 50% and
75% [1, 4], which is shown to significantly affect patients’
quality of life and may cause malnutrition, weight loss,
and increased morbidity [3, 5, 6].
Cytostatic and cytotoxic chemotherapeutics mainly in-
duce dysgeusia by destroying olfactory and taste receptor
structures due to their inherently high turnover rates of
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7 to 10 days. Several antineoplastic agents themselves
also have metallic- or bitter-tasting contents that can
reach taste receptors by diffusion through capillaries [1].
Direct sensitization or damage of neurons, moreover,
can alter afferent taste pathways without the need for
destroyed receptor cells or bad-tasting molecules from
chemotherapeutic drugs [3]. Other chemotherapy side
effects, such as oral mucositis, gastroesophageal reflux,
or infections, and the intake of antibiotics or analgesics
used to manage these side effects can exacerbate existing
taste disturbances [2, 7].
Evidence for effective pharmacological treatment strat-
egies of chemotherapy-induced dysgeusia is limited.
Although current studies do not support the intake of
amifostine [8, 9] or the substitution with zinc [10] or glu-
tamine [11], dietetic counseling has provided the best
available evidence to date and is recommended by several
systematic reviews [1–3, 12] and the American Institute
for Cancer Research. The effects of acupuncture for the
treatment of dysgeusia have been examined in only one
pilot trial in 37 patients with idiopathic dysgeusia, showing
significant benefits of selected body and ear acupuncture
points over sham acupuncture [13]. A literature search of
standard medical databases revealed no randomized con-
trolled acupuncture trials for dysgeusia in patients under-
going chemotherapy [14], but evidence was found for
several other chemotherapy-related symptoms, such as
nausea and vomiting and leukopenia, and a lower quality
of evidence for pain, hot flashes, fatigue, and xerostomia
[15–17]. Because in Traditional Chinese Medicine, taste
disorders and functional disturbances of the tongue were
particularly treated with needling of hypoglossal acupunc-
ture points [18, 19], the aim of the present study is to
investigate the effects of acupuncture under the tongue
for acute chemotherapy-induced dysgeusia.
Methods/design
Objectives
The aim of this study is to examine the efficacy and
safety of hypoglossal acupuncture in the treatment of
acute dysgeusia in patients with breast cancer undergo-
ing chemotherapy.
Ethics
The trial protocol has been approved by the ethics com-
mittee of the Medical Faculty of the University of
Duisburg-Essen, Germany (approval number 14–5953-
BO), is registered with ClinicalTrials.gov (NCT02304913),
and will be conducted in accordance with the ethical prin-
ciples for clinical trials as defined by the Declaration of
Helsinki. Before inclusion in the study, all patients have to
provide written informed consent.
Study design
The study is a randomized controlled clinical trial com-
paring verum acupuncture with two active comparators:
sham acupuncture and standard medical care. It is de-
signed according to the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) 2013
statement [20], the Consolidated Standards of Reporting
Trials (CONSORT) 2010 statement [21], and its Standards
for Reporting Interventions in Clinical Trials of Acupunc-
ture (STRICTA) 2010 extension [22]. If patients develop
dysgeusia during chemotherapy and meet the eligibility
criteria of this study, baseline data will be assessed at the
individual’s next chemotherapy appointment, directly be-
fore chemotherapy administration (T0). Afterward, pa-
tients will be randomized 1:1:1 to one of the three groups.
Patients of the acupuncture groups will receive either
verum or sham acupuncture; patients of the standard
medical care group will receive written, evidence-based
dietary recommendations. Outcomes will be reassessed
just before the next chemotherapy administration (T2) as
well as between the chemotherapy administrations using a
daily patient log (T1–2) (Figs. 1 and 2). Patient recruitment
started in January 2015. Estimated primary completion
date is December 2019.
Randomization
A researcher who was not involved in conducting the
study generated a stratified (by age and type of chemo-
therapy because both variables are found to affect the
course of dysgeusia [23, 24]) random allocation se-
quence with randomly varying block lengths using
Random Allocation Software [25]. The randomization
list is password-secured, and no person other than the
aforementioned researcher is able to access it. On the
basis of this list, the researcher prepared sealed and
opaque envelopes sorted in ascending order of
randomization. Allocation to the groups will be
executed by the study physician, who is involved in
neither the random sequence generation nor the
assessment of study outcomes.
Blinding
First, patients of the two acupuncture groups will be
blinded to whether they receive verum or sham acu-
puncture. Second, the outcome assessors delivering
questionnaires to patients will remain blind to patients’
group allocations during the whole study period. Third,
the statistician will be blinded to group allocation during
data analysis by renaming groups with numbers.
Participants
Patients will be recruited from the Department of
Gynecology & Gynecologic Oncology, Kliniken Essen-
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Mitte, Germany. Interested patients with symptoms of
phantogeusia are screened by the attending physician
and receive detailed written study information and have
an enrollment visit with the study physician on the day
of their next chemotherapy administration. For inclusion
in the study, all eligibility criteria have to be met and
written informed consent must be obtained from the
patient prior to inclusion.
Inclusion criteria are as follows:
 Patients with breast cancer (TNM stages I–III)
undergoing initial treatment with platinum- or
taxane-based chemotherapy (regardless of the length
of the chemotherapy cycle)
 Phantogeusia intensity of 4 points or above on
average on an 11-point numeric rating scale
(NRS) since the last chemotherapy
administration
 Willingness to participate in the study and provision
of written informed consent
Exclusion criteria are as follows:
 Severe stomatitis
 Dysgeusia before chemotherapy (based on
neurological diseases, diabetes, or ingestion of drugs
with taste disorders as a side effect)
 Leukopenia/neutropenia
 Treatment with anticoagulants and/or hemophilia
 Smoker
 Severe physical or mental comorbidity (whereby the
patient is unable to participate in the study)
 Use of other complementary treatments that might
influence patients’ taste
 Participation in other studies of interventions for
oral complications due to chemotherapy
Fig. 1 CONSORT flow chart
Haller et al. Trials          (2019) 20:398 Page 3 of 7
Interventions
Verum acupuncture group
Patients of the verum group receive a single treatment
of hypoglossal needle acupuncture during their next
chemotherapy administration after study inclusion.
Treated acupuncture points will be Jinjin (Golden Li-
quid/EX-HN12) left beside the lingual frenulum and
Yuye (Jade Fluid/EX-HN13) right beside the lingual
frenulum. Both points are treated in quick succession
with immediate removal of the needle (Table 1).
Nonpenetrating sham acupuncture group
Patients of the sham group receive sham acupuncture
under the tongue also during their next chemotherapy
administration after study inclusion. Treated points will
be 1 to 1.5 cun (a cun is defined as the width of the
patient’s thumb at the knuckle) beside the verum
acupuncture points Jinjin and Yuye using the dull side of
the needle [26, 27].
Standard medical care group
Patients of the standard medical care group receive
evidence-based dietary recommendations for dysgeusia
[2, 12] during their first chemotherapy administration
after study inclusion. Dietary advice will be provided by
the study physician based on a self-help book of the Ger-
man Cancer Society [28]. This self-help book was also
given to the patients to take home.
Data collection
Baseline data will be assessed before randomization (T0)
and will include social demographics (age, sex, family
status, education, employment), medical data of the
patient (tumor type, staging, grading, relapse, meno-
pausal status, chemotherapy type), and ratings for base-
line outcome data.
Primary outcome
The primary outcome is phantogeusia [11, 29, 30], a con-
tinuous abnormal taste sensation without an external oral
stimulus, as assessed at follow-up (T2) by an 11-point NRS.
Secondary outcomes
Secondary outcomes include phantogeusia, assessed be-
tween T1 and T2 using a daily patient log, as well as
parageusia (abnormal taste of food), hypogeusia (reduced
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taste sensations), hypergeusia (increased taste sensa-
tions), xerostomia (dry mouth), stomatitis symptoms,
appetite, and functional/social impairment, assessed at
T2 and between T1 and T2 using a daily patient log with
11-point NRSs, respectively.
Safety assessment
All adverse events will be recorded and assessed by the
study physician at T2. According to good clinical practice
guidelines, adverse events are defined as any untoward
medical occurrence in the patient administered a medicinal
product and that does not necessarily have a causal rela-
tionship with this treatment [31]. Thereby, serious adverse
events are defined as any untoward medical occurrence
that at any dose resulted in death, was life-threatening, re-
quired inpatient hospitalization, or resulted in persistent or
significant disability/incapacity [31]. All participants will
further be asked about any such event during the study
period (between T1 and T2) and at follow-up (T2).
Treatment expectancy and credibility
Treatment expectancy and credibility will be assessed by
the Treatment Credibility Scale [32, 33] and the Bang
blinding index [34, 35] to examine possible confounding
effects due to expectation and conditioning and to con-
trol the success of the blinding toward the verum and
sham acupuncture. Expectancy will be assessed at base-
line (T0), and credibility will be assessed directly after
the acupuncture treatment (T1) and at follow-up (T2).
Sample size calculation
No study has yet investigated the effect of hypoglossal
acupuncture for chemotherapy-induced dysgeusia; as
such, a sample size estimation on the basis of previous
effect sizes was not possible. Therefore, a sample size of
n = 25 patients per group was considered sufficient to
detect an effect of d = 0.8, using a two-sided t test
between independent groups (verum acupuncture versus
standard medical care) with an α of 0.05 and a power of
1 − β = 0.8, as calculated using G*Power software
(release 3.1.3; Kiel University, Kiel, Germany) [36].
Statistical analysis
Data will be analyzed using IBM SPSS Statistics for
Windows software, release 22.0 (IBM Corp., Armonk,
NY, USA). Patients’ characteristics will be presented
separately for each group using descriptive statistics, in-
cluding mean and standard deviation, median and range,
Table 1 Details of the acupuncture treatment according to STRICTA
STRICTA items Detailed protocol description
Acupuncture rationale (a) Style of acupuncture Traditional Chinese needle acupuncture
(b) Reasoning for treatment provided Selected traditional acupuncture points for dysfunction of the tongue
(c) Extent to which treatment was varied Acupuncture with immediate removal of the needle
Details of needling (a) Number of needle insertions Two needle insertions per subject
(b) Names of points used Jinjin (Ex-HN 12), Yuye (Ex-HN13)
(c) Depth of insertion 1–2 mm
(d) Response sought No De-Qi sensation
(e) Needle stimulation No stimulation
(f) Needle retention time 2–3 s for each acupuncture point
(g) Needle type TeWa CB-Type 2540 (0,25 × 40 mm), medical stainless steel with copper
handle (asia-med GmbH & Co. KG, Germany)
Treatment regimen (a) Number of treatment sessions Single treatment session
(b) Frequency and duration of treatment
sessions
During the received chemotherapy administration
Other components of
treatment
(a) Details of concurrent interventions No concurrent interventions
(b) Setting and context of treatment Outpatient clinic, all treatments in a specific study center will be performed
by the same practitioner
Practitioner background (a) Description of participating
acupuncturists
Licensed Traditional Chinese Medicine practitioner with 5 years of studies
at the Tianjin University (China) and 3 years of acupuncture treatment
experience in a clinical oncological setting
Control or comparator
interventions
(a) Rationale for the control or
comparator
Non-penetrating sham acupuncture
(b) Precise description of the control
or comparator
Sham points: 1 to 1.5 cun (1 to 1.5 thumb’s width) beside the verum
acupuncture points using the dull side of the needle
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frequencies and proportions, based on the data format
and distribution.
Data analysis will be conducted according to the
intention-to-treat principle; that is, all randomized
patients regardless of compliance or withdrawal will be
included. Missing values will be multiply imputed by the
Markov chain Monte Carlo method [37, 38], yielding a
total of 50 complete datasets. Statistical tests will be
conducted in a hierarchical order, starting with the com-
parison of acupuncture vs. usual care, which in case of
significant effects will be followed by the comparison of
acupuncture vs. sham acupuncture.
The primary outcome will be analyzed as a function of
the treatment group (verum acupuncture versus stand-
ard medical care), patients’ expectations, and their
respective baseline values (linear covariates) using a uni-
variate analysis of covariance. Between-group differences
and 95% confidence intervals were estimated using two-
sided t tests and an alpha level of 5%. If the analysis re-
veals a statistically significant between-group difference,
a second univariate analysis of covariance on the
primary outcome will be conducted as a function of the
treatment group (verum acupuncture versus sham acu-
puncture), patients’ expectations, and their respective
baseline values (linear covariates). Between-group differ-
ences and 95% confidence intervals were estimated using
two-sided t tests and an alpha level of again 5%. Because
of hierarchical testing of the hypotheses, no alpha level
adjustment is necessary [39]. The same covariance
models will be applied for secondary outcome measures;
for those effect measures, confidence intervals and P
values will be reported descriptively. Moreover, a
Kaplan-Meier survival analysis will be used to analyze
group differences regarding the time point of symptom
relief based on the daily patient log. Data on tolerability
and safety will be reported descriptively. No interim ana-
lysis will be conducted.
Discussion
Dysgeusia is often discussed as a less impairing, less sig-
nificant side effect of chemotherapy. For patients, how-
ever, taste distortions during chemotherapy greatly affect
appetite and quality of life, with few available effective
treatment options [3, 6, 10]. Acupuncture as a relatively
simple and short intervention that did not show severe
side effects during the application of chemotherapy [17]
and preliminary effects in patients with idiopathic dys-
geusia [13] appears to be an important subject of re-
search. The present trial was rigorously designed
according to the CONSORT and STRICTA recommen-
dations, including a nonpenetrating sham needling con-
trol, blinding of outcome assessors and patients,
controlling of blinding success and expectation effects,
and the use of standardized NRSs [22]. Particularly
regarding the design of an ideal sham acupuncture con-
trol procedure, researchers broadly discussed how to
mimic best the procedure of acupuncture and control
for unspecific effects of expectation, conditioning, and
therapeutic attention without provoking specific physio-
logical effects [40–42]. It was argued that noninvasive
sham acupuncture appears to be a more suitable control
condition than the minimally invasive approach. In this
study, using a noninvasive sham procedure should be
feasible and blindable because participants do not have a
visual control.
This trial should therefore generate the first evidence
for the efficacy and effectiveness of hypoglossal acupunc-
ture in patients with breast cancer who have acute
chemotherapy-induced dysgeusia. Results can provide
suitable information for further sham protocols and clin-
ical acupuncture trials.
Trial status
This randomized clinical trial is currently recruiting
participants.
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